Hoth Therapeutics, Inc., was incorporated under the laws of the State of Nevada on May 16, 2017. The company is a developing biopharmaceutical company focused on providing targeted therapies for patients with diseases such as atopic dermatitis (also known as eczema). The Company's primary asset is a sub-license agreement with Chelexa, under which Chelexa has granted an exclusive sub-license to use its BioLexa platform, a proprietary, patented, pharmaceutical compound platform developed at the University of Cincinnati. The license allows the development of the platform for any indication in humans. The company's initial focus will be on treating eczema through the application of topical creams. The BioLexa platform combines FDA-approved zinc chelating agents with one or more approved antibiotics in a topical dosage form to address unchecked eczema flares by preventing the formation of infectious biofilms and the resulting blockage of sweat ducts that cause symptoms. The company is the first product candidate designed to prevent symptoms from triggering emergencies rather than simply treating them when they appear.